PHAS
Income statement / Annual
Last year (2021), PhaseBio Pharmaceuticals, Inc.'s total revenue was $10,831.00,
a decrease of 96.62% from the previous year.
In 2021, PhaseBio Pharmaceuticals, Inc.'s net income was -$131,071.00.
See PhaseBio Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$10,831.00
|
$320,000.00
|
$2.36 M
|
$668,000.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$0.00 |
$319,680.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$10,831.00 |
$320.00 |
$2.36 M |
$668,000.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
1 |
0 |
1 |
1 |
0 |
0 |
| Research and Development
Expenses |
$102,107.00
|
$72.09 M
|
$30.91 M
|
$15.46 M
|
$6.21 M
|
$7.38 M
|
| General & Administrative
Expenses |
$16,086.00
|
$13.09 M
|
$11.19 M
|
$4.86 M
|
$2.33 M
|
$2.13 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$16,086.00
|
$13.09 M
|
$11.19 M
|
$4.86 M
|
$2.33 M
|
$2.13 M
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$118,193.00 |
$85.18 M |
$42.10 M |
$20.31 M |
$8.54 M |
$9.50 M |
| Cost And Expenses |
$118,193.00 |
$85.18 M |
$42.10 M |
$20.31 M |
$8.54 M |
$9.50 M |
| Interest Income |
$14.00 |
$237,000.00 |
$1.58 M |
$387,000.00 |
$52,000.00 |
$29,000.00 |
| Interest Expense |
-$947.00 |
$1.45 M |
$1.08 M |
$3.92 M |
$2.72 M |
$0.00 |
| Depreciation &
Amortization |
$1.79 M
|
$508,000.00
|
$174,000.00
|
$105,000.00
|
$96,000.00
|
$92,000.00
|
| EBITDA |
$1.66 M
|
-$96.61 M
|
-$38.00 M
|
-$19.82 M
|
-$7.43 M
|
-$9.13 M
|
| EBITDA Ratio |
153.5 |
-301.91 |
-16.09 |
-29.67 |
0 |
0 |
| Operating Income Ratio
|
-12.04
|
-265.18
|
-16.83
|
-29.41
|
0
|
0
|
| Total Other
Income/Expenses Net |
$947.00
|
-$13.71 M
|
$489,000.00
|
-$4.20 M
|
-$1.71 M
|
$281,000.00
|
| Income Before Tax |
-$129,471.00 |
-$98.57 M |
-$39.25 M |
-$23.85 M |
-$10.25 M |
-$9.22 M |
| Income Before Tax Ratio
|
-11.95
|
-308.02
|
-16.62
|
-35.7
|
0
|
0
|
| Income Tax Expense |
$1,600.00 |
-$12.26 M |
$1.57 M |
-$278,000.00 |
$1.01 M |
$281,000.00 |
| Net Income |
-$131,071.00 |
-$98.57 M |
-$39.25 M |
-$23.85 M |
-$10.25 M |
-$9.22 M |
| Net Income Ratio |
-12.1 |
-308.02 |
-16.62 |
-35.7 |
0 |
0 |
| EPS |
-0.0045 |
-3.39 |
-1.43 |
-4.49 |
-0.91 |
-0.74 |
| EPS Diluted |
-0.0045 |
-3.39 |
-1.43 |
-4.49 |
-0.91 |
-0.74 |
| Weighted Average Shares
Out |
$29.40 M
|
$29.06 M
|
$27.49 M
|
$5.31 M
|
$11.25 M
|
$12.39 M
|
| Weighted Average Shares
Out Diluted |
$29.40 M
|
$29.06 M
|
$27.49 M
|
$5.31 M
|
$11.25 M
|
$12.39 M
|
| Link |
|
|
|
|
|
|
